Welcome to our dedicated page for Vext Science news (Ticker: VEXTF), a resource for investors and traders seeking the latest updates and insights on Vext Science stock.
Vext Science, Inc. (VEXTF) is a vertically integrated U.S. cannabis operator with cultivation, manufacturing, and retail operations in Arizona and Ohio. This page provides investors and industry observers with direct access to official company announcements, including earnings reports, regulatory updates, and strategic initiatives.
Track Vext Science's progress through press releases detailing operational expansions, product innovations under its Vapen brand, and compliance milestones in medical and adult-use markets. Our curated collection ensures timely access to material developments affecting the company's position as a leader in THC concentrate production and cost-efficient facility build-outs.
Key updates include manufacturing advancements, retail dispensary openings, licensing achievements, and financial performance. Bookmark this page to monitor how Vext Science leverages its fully integrated model to maintain quality control across its supply chain while adapting to evolving cannabis regulations.
Vext Science announced its Q1 2024 financial results, highlighting a revenue of $8.4 million, compared to $9.1 million in Q1 2023. The adjusted EBITDA stood at $1.9 million, a decrease from $2.9 million in Q1 2023. The EBITDA margin improved to 23.3% from 6.5% in Q4 2023. The company is preparing for the anticipated adult-use program in Ohio, leveraging its vertically-integrated operations. A $2 million standby credit facility has been secured to support operations and expansion in Ohio. CEO Eric Offenberger emphasized the potential growth in Ohio despite consumer challenges in Arizona. The company plans to enhance cash flow and shareholder returns with modest capital expenditures and strategic financial flexibility.
Vext Science (CSE: VEXT, OTCQX: VEXTF), a U.S.-based cannabis operator in Arizona and Ohio, announced it will release its Q1 2024 financial results on May 29, 2024, before market open.
The results will cover the quarter ended March 31, 2024.
A conference call and webcast will follow at 8:00 a.m. ET on the same day.
Dial-in numbers for the call are +1-647-484-8814 or 1-844-763-8274, with a replay available until June 12, 2024, at +1-604-674-8052 or 1-855-669-9658, using conference ID 10023534.
Webcast access is provided through https://www.gowebcasting.com/13356. For further details, contact investors@vextscience.com.
Vext Science, Inc. reported a revenue of $34.8 million for 2023 with Adjusted EBITDA of $5.5 million. The company is set to launch an adult-use program in Ohio for significant growth. Ohio expansion includes a cultivation facility, manufacturing facility, and four dispensaries. Despite market challenges, Vext performed well in Q4, positioning itself for growth in Ohio's $4 billion cannabis market. Recent acquisitions and debt conversions indicate strategic moves for Vext's expansion.
Vext Science, Inc. announces new date for Q4 and fiscal 2023 financial results release. The company will release its financial results for the period ended December 31, 2023, on May 10, 2024, and host a conference call and webcast on the same day at 1:00 p.m. ET.
FAQ
What is the current stock price of Vext Science (VEXTF)?
What is the market cap of Vext Science (VEXTF)?
